Assuntos
Doenças Fetais/imunologia , Hipóxia-Isquemia Encefálica/imunologia , Interleucina-1beta/metabolismo , Acidose/imunologia , Acidose/fisiopatologia , Proteínas de Transporte/fisiologia , Doenças Fetais/fisiopatologia , Humanos , Hipóxia-Isquemia Encefálica/fisiopatologia , Recém-Nascido , Inflamação/imunologia , Proteína 3 que Contém Domínio de Pirina da Família NLRRESUMO
Familial cold autoinflammatory syndrome (FCAS, MIM 120100), commonly known as familial cold urticaria (FCU), is an autosomal-dominant systemic inflammatory disease characterized by intermittent episodes of rash, arthralgia, fever and conjunctivitis after generalized exposure to cold. FCAS was previously mapped to a 10-cM region on chromosome 1q44 (refs. 5,6). Muckle-Wells syndrome (MWS; MIM 191900), which also maps to chromosome 1q44, is an autosomal-dominant periodic fever syndrome with a similar phenotype except that symptoms are not precipitated by cold exposure and that sensorineural hearing loss is frequently also present. To identify the genes for FCAS and MWS, we screened exons in the 1q44 region for mutations by direct sequencing of genomic DNA from affected individuals and controls. This resulted in the identification of four distinct mutations in a gene that segregated with the disorder in three families with FCAS and one family with MWS. This gene, called CIAS1, is expressed in peripheral blood leukocytes and encodes a protein with a pyrin domain, a nucleotide-binding site (NBS, NACHT subfamily) domain and a leucine-rich repeat (LRR) motif region, suggesting a role in the regulation of inflammation and apoptosis.
Assuntos
Doenças Autoimunes/genética , Proteínas Sanguíneas/genética , Proteínas de Transporte/genética , Temperatura Baixa/efeitos adversos , Febre Familiar do Mediterrâneo/genética , Mutação de Sentido Incorreto/genética , Proteínas/química , Motivos de Aminoácidos , Sequência de Aminoácidos , Doenças Autoimunes/complicações , Sequência de Bases , Proteínas Sanguíneas/química , Proteínas de Transporte/química , Mapeamento Cromossômico , Proteínas do Citoesqueleto , Análise Mutacional de DNA , Éxons/genética , Feminino , Perfilação da Expressão Gênica , Perda Auditiva Neurossensorial/complicações , Perda Auditiva Neurossensorial/genética , Humanos , Inflamação/complicações , Inflamação/genética , Íntrons/genética , Masculino , Dados de Sequência Molecular , Proteína 3 que Contém Domínio de Pirina da Família NLR , Linhagem , Estrutura Terciária de Proteína , Pirina , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Homologia de Sequência do Ácido NucleicoRESUMO
BACKGROUND: Familial cold autoinflammatory syndrome (FCAS), commonly known as familial cold urticaria, is a rare autosomal dominant inflammatory disorder with episodic symptoms precipitated by exposure to cold. OBJECTIVE: The goal of this study was to formulate clinical diagnostic criteria for FCAS in a large cohort in whom the diagnosis of FCAS was supported by genetic linkage to chromosome 1q44. METHODS: We assessed 45 affected and 68 unaffected members from 6 American families. DNA analysis was performed to confirm linkage to chromosome 1q44. Clinical characteristics were determined by means of analysis of detailed questionnaires and medical histories. RESULTS: Pedigree and genetic analyses confirmed autosomal dominant transmission and linkage to chromosome 1q44 in all families. The most consistent symptoms during attacks were rash (100%), fever (93%), arthralgia (96%), and conjunctivitis (84%). Age of onset was within the first 6 months of life in 95% of affected subjects. The average delay between cold exposure and onset of symptoms was 2.5 hours, and the average duration of an episode was 12 hours. Renal disease with amyloidosis occurs infrequently in FCAS (2%). CONCLUSION: The most consistent clinical characteristics of FCAS that discriminate it from other periodic fevers are association with cold exposure, conjunctivitis, age of onset, duration of episodes, and an autosomal dominant inheritance pattern. On the basis of the analysis of genotype and phenotype of FCAS, we formulated clinical diagnostic criteria that can be used to distinguish FCAS from other hereditary periodic fever syndromes.
Assuntos
Temperatura Baixa/efeitos adversos , Periodicidade , Urticária/diagnóstico , Urticária/genética , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Amiloidose/complicações , Artralgia/complicações , Criança , Pré-Escolar , Cromossomos Humanos Par 1 , Exantema/complicações , Oftalmopatias/complicações , Feminino , Genes Dominantes , Ligação Genética , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Linhagem , Síndrome , Urticária/complicaçõesRESUMO
Familial cold urticaria (FCU) is a rare autosomal dominant inflammatory disorder characterized by intermittent episodes of rash with fever, arthralgias, conjunctivitis, and leukocytosis. These symptoms develop after generalized exposure to cold. Some individuals with FCU also develop late-onset reactive renal amyloidosis, which is consistent with Muckle-Wells syndrome. By analyzing individuals with FCU from five families, we identified linkage to chromosome 1q44. Two-point linkage analysis revealed a maximum LOD score (Zmax) of 8.13 (recombination fraction 0) for marker D1S2836; multipoint linkage analysis identified a Zmax of 10. 92 in the same region; and haplotype analysis defined a 10.5-cM region between markers D1S423 and D1S2682. Muckle-Wells syndrome was recently linked to chromosome 1q44, which suggests that the two disorders may be linked to the same locus.
Assuntos
Cromossomos Humanos Par 1/genética , Temperatura Baixa , Urticária/genética , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Amiloidose/complicações , Amiloidose/genética , Amiloidose/fisiopatologia , Criança , Pré-Escolar , Mapeamento Cromossômico , Doenças em Gêmeos/genética , Feminino , Genes Dominantes/genética , Marcadores Genéticos/genética , Haplótipos/genética , Humanos , Lactente , Nefropatias/complicações , Nefropatias/genética , Nefropatias/fisiopatologia , Escore Lod , Masculino , Pessoa de Meia-Idade , Linhagem , Penetrância , Software , Síndrome , Urticária/complicações , Urticária/fisiopatologiaRESUMO
BACKGROUND: Budesonide (Pulmicort) is an inhaled corticosteroid with high topical potency but low systemic activity. Turbuhaler is a novel breath-actuated, multi-dose, dry-powder inhaler. OBJECTIVES: This study was conducted to determine the efficacy and safety of two different dose regimens of budesonide Turbuhaler, compared with placebo, in adult patients with mild-to-moderate asthma not well-controlled with bronchodilator therapy. METHODS: This double-blind, randomized, placebo-controlled, parallel-group, multicenter study compared the efficacy and safety of 200 microg and 400 microg of budesonide, administered twice daily via Turbuhaler, with placebo, in 273 adult patients (aged 19 to 70 years) with mild-to-moderate asthma (FEV1 67% of predicted normal), not well-controlled with bronchodilator therapy. Efficacy was assessed by pulmonary function tests and patient assessments of asthma symptom control. Safety was assessed in terms of adverse events, laboratory evaluations, and physical examinations. RESULTS: Two hundred and 400 microg of budesonide bid were significantly more effective than placebo at improving morning PEF (mean differences from placebo of 43.63 L/min and 40.10 L/min, respectively; P < .001) and FEV1 (mean differences from placebo of 0.44 L, and 0.50 L, respectively; P < .001) over the 12-week treatment period. Onset of action as assessed by morning PEF was within two days. Basal and stimulated plasma cortisol concentrations were not significantly affected by budesonide treatment compared with placebo. CONCLUSIONS: Treatment of adults suffering from mild-to-moderate asthma with budesonide Turbuhaler is well tolerated and results in a rapid onset of asthma control which is maintained over time.
Assuntos
Asma/prevenção & controle , Broncodilatadores/farmacocinética , Budesonida/farmacocinética , Administração por Inalação , Adulto , Idoso , Broncodilatadores/administração & dosagem , Budesonida/administração & dosagem , Feminino , Volume Expiratório Forçado , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Placebos , Índice de Gravidade de Doença , Equivalência TerapêuticaRESUMO
Recently, a product (SULFITEST; Center Laboratories) has become available for detecting the presence of sulfiting agents in foods. Testing with SULFITEST by the indirect method (ie, holding the test strip above the food product) or the direct method (ie, touching the test strip directly on the food) was associated with false negative results in five out of nine acidic sulfite-containing foods. Quantitative studies also confirmed that low pH conditions and/or the presence of ascorbic acid caused SULFITEST results by the direct method to significantly underestimate known concentrations of sulfites. Dependence on this sulfite detection strip may lead to unrecognized ingestion of sulfiting agents, especially in acidic and/or ascorbic acid-containing foods.
Assuntos
Aditivos Alimentares/análise , Análise de Alimentos/métodos , Fitas Reagentes , Sulfitos/análise , Ácido Ascórbico/farmacologia , Reações Falso-Negativas , Concentração de Íons de HidrogênioRESUMO
The acquired cold urticaria (ACU) syndromes consists of nonfamilial heterogeneous disorders characterized by urticaria, angioedema, and occasionally symptoms of hypotension after cold exposure. In a study of 50 consecutive patients with ACU syndromes, it was observed that 70% experienced cold-induced systemic reactions, most frequently with aquatic activities. Patients with ACU syndromes were categorized by their response to an experimental cold-stimulation time test (CSTT) i.e., minimum time threshold of cold stimulation required to induce a coalescent wheal. One subpopulation of patients with ACU syndromes with positive CSTTs of 3 minutes or less experienced the highest incidence (68%; 13/19) of severe systemic reactions with hypotensive symptoms after natural cold exposure. However, 32% of patients with ACU syndromes (6/19) who experienced cold-induced systemic reactions with hypotension had a negative CSTT or a positive test of greater than 3 minutes. These observations indicate that all patients with ACU with active histories of cold urticaria are at risk to develop systemic reactions to cold and should therefore refrain from participating in aquatic activities. In addition, high-risk patients should receive prophylactic medications (i.e., cyproheptadine or doxepin) that are effective in suppressing this disorder. A diagnostic classification of cold urticaria is presented. This classification permits a more specific definition of the various cold urticaria disorders that comprise the ACU syndromes.
Assuntos
Temperatura Baixa/efeitos adversos , Urticária/etiologia , Adolescente , Adulto , Criança , Pré-Escolar , Ciproeptadina/uso terapêutico , Doxepina/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Urticária/diagnóstico , Urticária/prevenção & controleRESUMO
We investigated the possibility that the inflammatory reaction in primary acquired cold urticaria might be associated with the release of platelet-activating factor. Six patients with the disease and five normal controls were subjected to cold-water challenges during which blood samples were obtained for measurement of the release of possible mediators: i.e., histamine, neutrophilic chemotactic activity, and platelet-activating factor-like lipid (PAF-LL). Four of the patients had pronounced experimentally induced cold urticaria with angioedema and release of mediators. Levels of the three mediators were not elevated in five normal controls or in two patients in whom cold challenges induced only mild urticaria and angioedema. The effective suppression of cold-induced urticaria in three patients treated with doxepin correlated with inhibition of PAF-LL release but not inhibition of histamine or neutrophilic chemotactic activity release. These data suggest a positive correlation between PAF-LL release and cold urticaria, although the exact relation between PAF-LL and cutaneous lesions of primary acquired cold urticaria has not yet been established.
Assuntos
Temperatura Baixa/efeitos adversos , Fator de Ativação de Plaquetas/análise , Urticária/sangue , 1-Alquil-2-acetilglicerofosfocolina Esterase , Adulto , Angioedema/sangue , Bioensaio , Quimiotaxia de Leucócito , Cromatografia em Camada Fina , Feminino , Liberação de Histamina , Humanos , Masculino , Fosfolipases A/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Serotonina/metabolismo , Trítio , Urticária/imunologiaRESUMO
A patient was seen with cold urticaria and urticarialike lesions with palpable purpura, acquired hypocomplementemia, low levels of circulating immune complexes, and skin biopsy evidence of necrotizing vasculitis. The association of cold urticaria with urticarialike vasculitis may represent a previously unrecognized subset of urticarial vasculitis.
Assuntos
Temperatura Baixa/efeitos adversos , Leucócitos/citologia , Urticária/etiologia , Vasculite/etiologia , Adulto , Proteínas do Sistema Complemento/análise , Edema/etiologia , Feminino , Imunofluorescência , Humanos , Jejuno , Transtornos da Pigmentação/etiologia , Prednisona/uso terapêutico , Púrpura/etiologia , Pele/análise , Urticária/tratamento farmacológico , Urticária/imunologia , Vasculite/imunologiaAssuntos
Temperatura Baixa/efeitos adversos , Urticária/etiologia , Adulto , Clima , Febre/etiologia , Humanos , Masculino , Linhagem , Urticária/genéticaRESUMO
Eight subjects with primary-acquired cold urticaria were treated with chlorpheniramine maleate, cyproheptadine hydrochloride, and placebo in a double-blind clinical trial. During three separate seven-day treatment periods, each patient took 4 mg of either active drug or lactose placebo three times a day. Objective measurements were made at the beginning and end of each treatment period by establishing the minimum time (MT) of cold stimulus application required to provoke urtication. In addition, the spontaneous appearance of cold urticaria lesions was recorded during each treatment period. The MT required for induction of urtication with a cold stimulus was significantly greater for eight patients receiving cyproheptadine as compared to chlorpheniramine or placebo (P less than .01). The study demonstrated that cyproheptadine had a significant suppressive action on experimental cold-induced urticaria, while placebo and chlorpheniramine proved ineffective.